Keith Meadors joins Precipio to lead its Products division

Precipio, Inc.

Seasoned, industry-experienced executive with experience managing 9-figure sales organizations

NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) — A cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO)announced today that Keith Meadors has joined Precipio as Senior Vice President of its Products Division, to manage and drive the company’s growth and market share.

Keith brings over 30 years of leadership experience in various healthcare organizations, including his recent role as Vice President of Marketing at Fresenius Kabi, a global healthcare company specializing in life-saving medicines and technologies, headquartered in Bad Homburg, Germany, with US headquarters in Lake Zurich, Illinois. During his 8 year tenure, Keith’s organization expanded its product portfolio to include the Agilia Infusion System, IV Solutions and Halo CSTD. Keith also led commercial marketing efforts in the recent acquisition of Ivenix, Inc. for a combined purchase price of $240 million.

Previously, Keith held several roles at Hospira (acquired by Pfizer in 2015 for $17 billion), where he served as district manager, director of pricing and strategic contracts, and district sales manager. Keith also worked at Becton Dickinson Diagnostics Systems, a global leader in products and instruments used for the diagnosis of infectious diseases, in a variety of sales, marketing and business development roles.

“I am thrilled to have Keith join the Precipio team. His vast experience and expertise is exactly what we need in the Products division,” said Ilan Danieli, CEO of Precipio. “Keith’s addition to the team further underscores the potential the company sees in the Products division, and the importance of bringing in talent of his caliber, to capitalize on the potential of the business.”

“It is an honor to join the distinguished team at Precipio, and I am delighted to share my own expertise and knowledge of product growth and development with the Product Division team. My mission is to lead the Products Division to increase revenue, gain visibility and reach the market,” said Keith Meadors, Senior Vice President of the Products Division at Precipio.

About Precipio

Precipio has built a robust specialty cancer diagnostics platform that enables the rapid development of highly differentiated, proprietary clinical diagnostic products that deliver superior clinical, operational and economic benefits to laboratories worldwide. Precipio leverages its relationships with world-class academic institutions, coupled with its in-house clinical laboratory that enables its in-house product development and testing engine to create and offer proprietary tests and reagents that improve accuracy diagnosis and improve patient care. For more information, please visit www.precipiodx.com.

Please follow us on LinkedInon Twitter @PrecipioDx and on Facebook.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements relating to forecasts or the potential impact of the novel coronavirus (COVID-19) pandemic, and related government, consumer and business responses, on our business, financial condition and results of operations, and any such forward-looking statements, whether relating to the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Excluding historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flow , plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could”, “may”, “expect”, “anticipate”, “will”, “target”, “goals”, “project”, “intend”, “plan” , “believes”, “seeks”, “estimates”, “forecasts” and variations of these words, and similar expressions which reflect our current opinions with regard to future events and operational, economic and financial performance, are intended to identify these forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or that could affect the company’s ability to achieve its strategic objectives, include uncertainties related to the impact of COVID- 19 on the business, operations and employees of the company and the other factors which are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the company’s annual report on Form 10- K for the year ended December 31, 2021, as updated from time to time in the Securities and Exchange Commission Filings.

The company’s forward-looking statements in this press release are based on opinions, beliefs, hypotheses and expectations regarding future events and speak only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.

CONTACT: Inquiries: [email protected] +1-203-787-7888 Ext. 523

Comments are closed.